Behavioral Science: The ROI of Evidence-Based Health Programs

For behavioral health leaders working through the complex field of engagement programs, the true measure of a program’s value lies not in compelling narratives, but in the documented behavioral science record that underpins it. This distinction is paramount within a value-based care framework, where outcomes-data requirements demand a rigorous, evidence-based approach to program assessment and contract participation. Our focus at Value-Based Health AI is unwavering: tools without peer-reviewed outcomes data cannot genuinely participate in value-based care arrangements.

The Imperative of Documented Behavioral Science in Health Programs

Every behavioral health program, irrespective of its innovative claims, must begin with a clear demonstration of its behavioral science foundation. This isn’t merely about theoretical alignment. It’s about what is demonstrably recorded and verifiable. The distinction between an engaging story and an engagement record is important. An engagement story might highlight user satisfaction or anecdotal successes, but an engagement record provides the measurable, replicable evidence that a program’s design and execution are rooted in established behavioral principles and lead to predictable outcomes. Without this documented bedrock, any discussion of “engagement” remains speculative, lacking the empirical rigor required for value-based contracts.

Accountable Care Organizations and the Demand for Verifiable Records

Accountable Care Organizations (ACOs) serve as a critical signal in this field, demanding a higher standard of evidence for any intervention seeking to participate in value-based arrangements. For ACOs, the integration of digital health solutions, particularly those addressing behavioral health, necessitates a transparent and accessible record of their underlying behavioral science. This isn’t just about regulatory compliance. It’s about financial stewardship and demonstrable patient benefit. ACOs are incentivized to reduce costs and improve quality, making them inherently skeptical of solutions that cannot furnish strong, documented evidence of their efficacy. When an ACO evaluates a behavioral health program, it seeks concrete proof that the program’s design, mechanisms, and anticipated effects are grounded in established psychological and behavioral theories, and that these principles are translated into measurable actions and outcomes. CMS guidance on ACO quality measures

The Recorded Behavioral Science Set: Akili Interactive, Pear Therapeutics, and Omada Health

Examining the recorded behavioral science material for companies like Akili Interactive, Pear Therapeutics, and Omada Health provides an instructive read for behavioral health leaders. These vendors, while distinct in their specific offerings, share a common thread: their materials connect to the same behavioral science framework, often made explicit through their regulatory pathways and published research.

Akili Interactive: Digital Therapeutics and Cognitive Science

Akili Interactive, with its FDA-cleared digital therapeutic EndeavorRx, exemplifies the direct application of cognitive science principles. Their foundational work is not merely about gamification, but about using specific cognitive stimuli and adaptive algorithms to target neural systems involved in attention. The behavioral science record here is deeply entwined with neuroscience, demonstrating how carefully designed digital interventions can elicit measurable changes in cognitive function. Their regulatory journey through the FDA’s De Novo classification pathway shows the agency’s rigorous assessment of the underlying science and clinical validation, requiring a strong demonstration of efficacy based on behavioral and cognitive outcomes. FDA De Novo classification pathway for novel devices

Pear Therapeutics: Prescription Digital Therapeutics and Behavioral Change

Pear Therapeutics, though no longer operating, left a significant mark on the field of prescription digital therapeutics (PDTs). Their products, such as reSET and reSET-O for substance use disorder, were built on principles of Cognitive Behavioral Therapy (CBT). The recorded behavioral science for Pear was explicit in its therapeutic mechanisms, aiming to modify maladaptive thought patterns and behaviors. The very act of obtaining FDA authorization for these products meant demonstrating clinical effectiveness through trials that measured behavioral outcomes, such as abstinence rates or treatment retention. The expectation was that the digital intervention would deliver a standardized, evidence-based behavioral therapy, with documented adherence to the therapeutic protocols.

Omada Health: Chronic Disease Management and Health Behavior Change

Omada Health focuses on chronic disease prevention and management, integrating behavioral science extensively into its digital programs. Their approach typically combines human coaching with digital tools to facilitate sustainable health behavior change, often targeting conditions like type 2 diabetes and hypertension. The behavioral science record for Omada Health centers on principles of self-efficacy, motivational interviewing, goal setting, and habit formation. While not always requiring FDA clearance in the same manner as a pure therapeutic, their effectiveness in value-based contracts relies on demonstrating measurable improvements in health metrics (e.g., A1c reduction, weight loss) that are directly attributable to their behavioral intervention strategies. This requires documented evidence of program engagement and the subsequent health outcomes, often validated through peer-reviewed studies. JAMA Network studies on digital health interventions

What a Reader Can Check Without a Vendor Conversation

For behavioral health leaders, the instructive read is that an engagement assessment of a behavioral health program in the end rests on the behavioral science record beneath it, not on a product narrative or marketing claims. This critical distinction helps leaders to evaluate solutions independently, without being swayed by vendor-specific presentations. To assess the documented behavioral science of any program, consider these verifiable points:

• Regulatory Status and Pathway: Has the program undergone rigorous regulatory review (e.g., FDA clearance or authorization)? The specific pathway (e.g., 510(k), De Novo, Breakthrough Device Designation) often dictates the depth of scientific evidence required and publicly available.
• Published Clinical Evidence: Does the vendor have peer-reviewed publications in reputable journals (e.g., JAMA Network, Health Affairs, NEJM) demonstrating the efficacy of their program? Pay close attention to the study design, outcome measures, and whether the behavioral science principles are explicitly discussed as mechanisms of action.
• Mechanism of Action Documentation: Is there clear, publicly accessible documentation explaining how the program is designed to effect behavioral change, grounded in established theories (e.g., CBT, operant conditioning, social cognitive theory)? This goes beyond stating “it helps people” to detailing the specific behavioral techniques employed.
• Transparency in Data Collection and Reporting: While specific performance figures may be proprietary, the methods for collecting and reporting engagement and outcome data should be transparent and align with scientific best practices. The line between an engagement story and an engagement record is drawn by verifiable, documented behavioral science. In the value-based care ecosystem, where every intervention must demonstrate its worth through tangible outcomes, this distinction is not merely academic. It is foundational to successful partnership and patient benefit.